Negatively charged nanoparticles of about 50 nm in size permit the oral delivery of insulin and other peptide drugs by temporally enhancing the permeability of the intestinal wall.
This is a preview of subscription content, log in via an institution to check access.
References
Lundquist, P. & Artursson, P. Adv. Drug Deliv. Rev. 106 (Part B), 256–276 (2016).
Toth, I. et al. J. Med. Chem. 42, 4010–4013 (1999).
Maher, S. et al. Pharmaceutics 11, 41v63 (2019).
Pridgen, E. M. et al. Sci. Transl. Med. 5, 213ra167 (2013).
Abramson, A. et al. Science 363, 611–615 (2019).
Abramson, A. et al. Nat. Med. 25, 1512–1518 (2019).
Lamson, N. G., Berger, A., Fein, K. C. & Whitehead, K. A. Nat. Biomed. Eng. 4, https://doi.org/10.1038/s41551-019-0465-5 (2019).
Hubatsch, I. et al. Nat. Protoc. 2, 2111–2119 (2007).
Anderson, J. M. & Van Itallie, C. M. CSH Perspect. Biol. 1, aa002584 (2009).
Buckley, A. & Turner, J. R. CSH Perspect. Biol. 10, a029314 (2018).
Taverner, A. et al. J. Control. Release 210, 189–187 (2015).
Buckley, S. T. et al. Sci. Transl. Med. 10, eaar7047 (2018).
Zinman, B. et al. Diabetes Care 42, 2262–2271 (2019).
FDA. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes (2019).
Almansour, K. et al. J. Control Release 288, 111–125 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Artursson, P., Lundquist, P. A new opening for orally taken peptide drugs. Nat Biomed Eng 4, 12–13 (2020). https://doi.org/10.1038/s41551-019-0513-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-019-0513-1
- Springer Nature Limited